DMKJ
AKRO

David M. Knott Jr’s Akero Therapeutics AKRO Stock Holding History

David M. Knott Jr’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-6,419
Closed -$325K – 116
2023
Q3 		$325K Buy
6,419
+4,419
+221% +$206K 0.12% 60
2023
Q2 		$94K Buy
+2,000
New +$91.7K 0.04% 71

Other funds holding AKRO

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

David M. Knott Jr's AKRO Position: Q4 2023 in Review

David M. Knott Jr sold out of Akero Therapeutics (AKRO) in Q4 2023, closing a stake of 6,419 shares — an estimated $325K sold.

David M. Knott Jr first reported a position in AKRO in Q2 2023 and held it in 2 quarters. The position peaked at $325K in Q3 2023. 157 funds tracked by Wall St. Rank hold AKRO as of Q4 2023.

  • David M. Knott Jr reported no remaining Akero Therapeutics position as of Q4 2023 after selling out during the quarter.
  • David M. Knott Jr sold 6,419 Akero Therapeutics shares in Q4 2023, an estimated $325K.
  • David M. Knott Jr first reported a position in Akero Therapeutics in Q2 2023 and held it in 2 quarters.
  • David M. Knott Jr's Akero Therapeutics position peaked at $325K in Q3 2023.
  • 157 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2023.

Based on David M. Knott Jr's 13F filing for Q4 2023, filed 13 Feb 2024.